Anika Therapeutics Equity 2024

Anika Therapeutics Aktienanalyse

What does Anika Therapeutics do?

Anika Therapeutics Inc is a global biotechnology company specializing in the development and manufacturing of therapeutic products for orthopedic, ophthalmologic, and dermatologic treatment. It was founded in 1992 in Bedford, Massachusetts and has since maintained its headquarters there while expanding its operations worldwide. Business model Anika Therapeutics' business model is based on the development, manufacturing, and commercialization of innovative and cost-effective medical devices that use natural substances to enable rapid and powerful repair of the human body in various orthopedic, ophthalmologic, and dermatologic conditions. The company leverages its expertise in hyaluronan biology and technology to produce products based on this substance for the regeneration and healing of tissues such as cartilage, skin, and eyes. History Anika Therapeutics was founded by Charles Sherwood and Jeffrey Palmer to develop a synthetic hyaluronic acid product for the treatment of joint disorders. The first clinical study was conducted in 1996, and Anika received FDA approval for the product, marketed as Orthovisc, in 1999. Since then, Anika has expanded its presence in the industry through acquisitions, partnerships, and expansion into new geographical areas. Divisions Orthopedics In orthopedics, Anika Therapeutics offers a wide range of products for the treatment of joint disorders such as osteoarthritis and arthritis. These include Orthovisc, the company's original product, as well as Monovisc, a single-component viscosupplement that allows for easy injection into the joint, thus reducing the procedure and recovery time. Another product is Cingal, a combination product of hyaluronic acid and corticosteroid that provides effective pain relief. Ophthalmology Anika Therapeutics also manufactures products for ophthalmology. The company has a portfolio of products used for surgical procedures such as cataract surgery and vitrectomy (a surgery on the eye's vitreous body). These are available under the brand names Visian and Amvisc. Dermatology Anika Therapeutics is also active in dermatology, where it offers products for skin regeneration. This portfolio includes solutions such as Hyalofill, a hyaluronic acid-based filler substance used for restoring skin elasticity and treating wrinkles and scars. In summary, Anika Therapeutics is a global biotechnology company specializing in the development, manufacturing, and commercialization of therapeutic products in the field of orthopedics, ophthalmology, and dermatology. The company leverages its expertise in hyaluronan biology and technology to develop innovative and cost-effective medical devices that enable rapid and powerful repair of the human body in various conditions. Since its founding in 1992, the company has built a successful history of growth and expansion through acquisitions, partnerships, and expansion into new geographical areas. Anika Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Anika Therapeutics's Equity

Anika Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Anika Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Anika Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Anika Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Anika Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Anika Therapeutics stock

What is the equity of Anika Therapeutics this year?

Anika Therapeutics has equity of 212.26 M USD this year.

What was the equity of Anika Therapeutics compared to the previous year?

The equity of Anika Therapeutics has increased/decreased by -25.68% decreased compared to the previous year.

What impact does a high equity have on investors of Anika Therapeutics?

A high equity is advantageous for investors of Anika Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Anika Therapeutics?

A low equity can be a risk for investors of Anika Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Anika Therapeutics affect the company?

An increase in equity of Anika Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Anika Therapeutics affect the company?

A reduction in equity of Anika Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Anika Therapeutics?

Some factors that can affect the equity of Anika Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Anika Therapeutics so important for investors?

The equity of Anika Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Anika Therapeutics take to change the equity?

To change equity, Anika Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Anika Therapeutics pay?

Over the past 12 months, Anika Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anika Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Anika Therapeutics?

The current dividend yield of Anika Therapeutics is .

When does Anika Therapeutics pay dividends?

Anika Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anika Therapeutics?

Anika Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Anika Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anika Therapeutics located?

Anika Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anika Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anika Therapeutics from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Anika Therapeutics pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Anika Therapeutics in the year 2023?

In the year 2023, Anika Therapeutics distributed 0 USD as dividends.

In which currency does Anika Therapeutics pay out the dividend?

The dividends of Anika Therapeutics are distributed in USD.